72 related articles for article (PubMed ID: 22087021)
1. A new recombinant human apolipoprotein E mimetic peptide with high-density lipoprotein binding and function enhancing activity.
Zhao W; Du F; Zhang M; Sun S; Yu H; Fan D
Exp Biol Med (Maywood); 2011 Dec; 236(12):1468-76. PubMed ID: 22087021
[TBL] [Abstract][Full Text] [Related]
2. Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice.
Navab M; Anantharamaiah GM; Reddy ST; Hama S; Hough G; Grijalva VR; Wagner AC; Frank JS; Datta G; Garber D; Fogelman AM
Circulation; 2004 Jun; 109(25):3215-20. PubMed ID: 15197147
[TBL] [Abstract][Full Text] [Related]
3. Bacterial overexpression, isotope enrichment, and NMR analysis of the N-terminal domain of human apolipoprotein E.
Fisher CA; Wang J; Francis GA; Sykes BD; Kay CM; Ryan RO
Biochem Cell Biol; 1997; 75(1):45-53. PubMed ID: 9192073
[TBL] [Abstract][Full Text] [Related]
4. Replacement of helix 1' enhances the lipid binding activity of apoE3 N-terminal domain.
Redmond KA; Murphy C; Narayanaswami V; Kiss RS; Hauser P; Guigard E; Kay CM; Ryan RO
FEBS J; 2006 Feb; 273(3):558-67. PubMed ID: 16420479
[TBL] [Abstract][Full Text] [Related]
5. Substitution of the carboxyl-terminal domain of apo AI with apo AII sequences restores the potential of HDL to reduce the progression of atherosclerosis in apo E knockout mice.
Holvoet P; Danloy S; Deridder E; Lox M; Bernar H; Dhoest A; Collen D
J Clin Invest; 1998 Jul; 102(2):379-85. PubMed ID: 9664079
[TBL] [Abstract][Full Text] [Related]
6. A monomeric human apolipoprotein E carboxyl-terminal domain.
Fan D; Li Q; Korando L; Jerome WG; Wang J
Biochemistry; 2004 May; 43(17):5055-64. PubMed ID: 15109264
[TBL] [Abstract][Full Text] [Related]
7. Distinct Roles of Apolipoproteins A1 and E in the Modulation of High-Density Lipoprotein Composition and Function.
Filou S; Lhomme M; Karavia EA; Kalogeropoulou C; Theodoropoulos V; Zvintzou E; Sakellaropoulos GC; Petropoulou PI; Constantinou C; Kontush A; Kypreos KE
Biochemistry; 2016 Jul; 55(27):3752-62. PubMed ID: 27332083
[TBL] [Abstract][Full Text] [Related]
8. Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice.
Westerterp M; van der Hoogt CC; de Haan W; Offerman EH; Dallinga-Thie GM; Jukema JW; Havekes LM; Rensen PC
Arterioscler Thromb Vasc Biol; 2006 Nov; 26(11):2552-9. PubMed ID: 16946130
[TBL] [Abstract][Full Text] [Related]
9. Role of HDL apolipoprotein E in cellular cholesterol efflux: studies in apo E knockout transgenic mice.
Hayek T; Oiknine J; Brook JG; Aviram M
Biochem Biophys Res Commun; 1994 Dec; 205(2):1072-8. PubMed ID: 7802634
[TBL] [Abstract][Full Text] [Related]
10. Retention of α-helical structure by HDL mimetic peptide ATI-5261 upon extensive dilution represents an important determinant for stimulating ABCA1 cholesterol efflux with high efficiency.
Zheng Y; Patel AB; Narayanaswami V; Bielicki JK
Biochem Biophys Res Commun; 2013 Nov; 441(1):71-6. PubMed ID: 24129191
[TBL] [Abstract][Full Text] [Related]
11. Blockade of scavenger receptor class B type I raises high density lipoprotein cholesterol levels but exacerbates atherosclerotic lesion formation in apolipoprotein E deficient mice.
Kitayama K; Nishizawa T; Abe K; Wakabayashi K; Oda T; Inaba T; Amemiya Y
J Pharm Pharmacol; 2006 Dec; 58(12):1629-38. PubMed ID: 17331327
[TBL] [Abstract][Full Text] [Related]
12. ApoE induces serum paraoxonase PON1 activity and stability similar to ApoA-I.
Gaidukov L; Viji RI; Yacobson S; Rosenblat M; Aviram M; Tawfik DS
Biochemistry; 2010 Jan; 49(3):532-8. PubMed ID: 20025294
[TBL] [Abstract][Full Text] [Related]
13. Pegylation of high-density lipoprotein decreases plasma clearance and enhances antiatherogenic activity.
Murphy AJ; Funt S; Gorman D; Tall AR; Wang N
Circ Res; 2013 Jun; 113(1):e1-e9. PubMed ID: 23613182
[TBL] [Abstract][Full Text] [Related]
14. Macrophage paraoxonase 1 (PON1) binding sites.
Efrat M; Aviram M
Biochem Biophys Res Commun; 2008 Nov; 376(1):105-10. PubMed ID: 18762170
[TBL] [Abstract][Full Text] [Related]
15. Single-step purification of two functional human apolipoprotein E variants hyperexpressed in Escherichia coli.
Pillot T; Barbier A; Visvikis A; Lozac'h K; Rosseneu M; Vandekerckhove J; Siest G
Protein Expr Purif; 1996 Jun; 7(4):407-14. PubMed ID: 8776760
[TBL] [Abstract][Full Text] [Related]
16. Modulation of THP-1 macrophage and cholesterol-loaded foam cell apolipoprotein E levels by glycosphingolipids.
Garner B; Mellor HR; Butters TD; Dwek RA; Platt FM
Biochem Biophys Res Commun; 2002 Feb; 290(5):1361-7. PubMed ID: 11820771
[TBL] [Abstract][Full Text] [Related]
17. Modulation of the lipid binding properties of the N-terminal domain of human apolipoprotein E3.
Weers PM; Narayanaswami V; Ryan RO
Eur J Biochem; 2001 Jul; 268(13):3728-35. PubMed ID: 11432739
[TBL] [Abstract][Full Text] [Related]
18. Structural characterization of a low density lipoprotein receptor-active apolipoprotein E peptide, ApoE3-(126-183).
Raussens V; Mah MK; Kay CM; Sykes BD; Ryan RO
J Biol Chem; 2000 Dec; 275(49):38329-36. PubMed ID: 10986285
[TBL] [Abstract][Full Text] [Related]
19. The receptor binding domain of apolipoprotein E is responsible for its antioxidant activity.
Pham T; Kodvawala A; Hui DY
Biochemistry; 2005 May; 44(20):7577-82. PubMed ID: 15896001
[TBL] [Abstract][Full Text] [Related]
20. Anti-atherosclerotic effects of an improved apolipoprotein A-I mimetic peptide.
Suematsu Y; Kawachi E; Idemoto Y; Matsuo Y; Kuwano T; Kitajima K; Imaizumi S; Kawamura A; Saku K; Uehara Y; Miura SI
Int J Cardiol; 2019 Dec; 297():111-117. PubMed ID: 31519377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
